Table 1.

Demographics of the study population

	Demographic	Case N=76	Control N=126
Age	Years	63.4 (±10.6)	65.6 (±10.5)
Gender	Female	32 (42.1%)	50 (39.7%)
Race	White	68 (89.5%)	101 (80.2%)
	Asian	1 (1.3%)	3 (2.4%)
	Black	6 (7.9%)	19 (15.1%)
	Other	1 (1.3%)	2 (1.6%)
	Not reported	0 (0%)	1 (0.79%)
Tumor diagnosis	Breast	37 (48.7%)	63 (50%)
	Multiple myeloma	19 (25%)	39 (31%)
	Prostate	14 (18.42%)	17 (13.5%)
	Other	6 (7.9%)	7 (5.6%)
Bisphosphonate use	Pamidronate	6 (7.9%)	24 (19.0%)
	Zoledronic acid	56 (73.7%)	75 (59.5%)
	Pamidronate and zoledronic acid	14 (18.4%)	27 (21.4%)
Months of Bisphosphonate Treatment	Pamidronate	29.0 (±12.4)	38.6 (±40.6)
	Zoledronic Acid	25.7 (±121.7)	28.8 (±24.1)
	Zoledronic Acid plus Pamidronate	55.1 (±43.6)	51.0 (±36.2)
Radiation to head or neck area	Yes (%)	9 (11.8%)	0 (0%)
Tobacco use*	Prior or present	40 (52.6%)	24* (48.0%)
Alcohol use	Prior or present	34 (44.7%)	52 (41.3%)
Exposure to Bevacizumab	Yes (%)	20 (26.3%)	11 (8.7%)
Exposure to multiple classes of chemotherapy	Yes (%)	34 (44.7%)	65 (51.6%)
ONJ Characteristics at presentation	Mandible	29 (38.2%)	X
	Maxilla	11 (14.5%)	X
	Multiple lesions	34 (44.7%)	X
	Unspecified location(s)	2 (2.6%)	X
	Pain	29 (38%)	X
	Inflammation/Infection	24 (31.6%)	X

^*Tobacco data not available for 76 controls. All data reported as mean (± standard deviation) or n (%)